Who are supportive and immunosuppressive therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate, Elidel, Rapamune, SIROLIMUS, Cellcept, Prograf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/supportive-and-immunosuppressive-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

supportive and immunosuppressive therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

supportive and immunosuppressive therapy (supportive and immunosuppressive therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant Immunology Small molecule Live · refreshed every 30 min

Target snapshot

supportive and immunosuppressive therapy (supportive and immunosuppressive therapy) — RWTH Aachen University. Supportive and immunosuppressive therapy involves the use of medications to suppress the immune system and prevent rejection in organ transplant patients, while also providing supportive care to manage symptoms and improve quality of life.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
supportive and immunosuppressive therapy TARGET	supportive and immunosuppressive therapy	RWTH Aachen University	phase 3	Immunosuppressant
Mycophenolate	MYCOPHENOLIC ACID	Novartis	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	2004-01-01
Elidel	PIMECROLIMUS	Bausch Health	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A	2001-01-01
Rapamune	sirolimus	Pfizer	marketed	mTOR Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein kinase mTOR	1999-01-01
SIROLIMUS	SIROLIMUS		marketed	mTOR Inhibitor Immunosuppressant [EPC]	mTOR	1999-01-01
Cellcept	MYCOPHENOLATE MOFETIL	Roche Palo	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	1995-01-01
Prograf	TACROLIMUS	Astellas Pharma	marketed	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-08-30 — Prograf · 8685998 · Formulation · US
2028-08-30 — Prograf · 8664239 · Method of Use · US
2029-02-14 — Rapamune · 8911786 · Formulation · US
2030-04-15 — Rapamune · 10206887 · Formulation · US
2036-03-05 — Rapamune · 10705070 · Formulation · US
2036-03-05 — Rapamune · 12061183 · Formulation · US
2036-06-29 — Rapamune · 12133844 · Method of Use · US
2036-06-29 — Rapamune · 10973806 · Method of Use · US
2039-08-16 — Cellcept · 12097285 · Formulation · US
2039-08-16 — Cellcept · 11931455 · Formulation · US
2039-08-16 — Cellcept · 12226526 · Formulation · US
2039-08-16 — Cellcept · 12097284 · Formulation · US
2039-08-16 — Cellcept · 12194143 · Formulation · US
2040-10-28 — Rapamune · 11497737 · Formulation · US

Sponsor landscape (Immunosuppressant class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
I.M. Sechenov First Moscow State Medical University · 1 drug in this class
Kenya Medical Research Institute · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
RWTH Aachen University · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). supportive and immunosuppressive therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/supportive-and-immunosuppressive-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing